Startseite>>Signaling Pathways>> Others>>Fluorofenidone

Fluorofenidone (Synonyms: AKF-PD)

Katalog-Nr.GC38114

Fluorofenidon (AKF-PD), ein Analogon von AMR69, zeigt eine gleichwertige antifibrotische AktivitÄt, eine geringere ToxizitÄt und eine lÄngere Halbwertszeit.

Products are for research use only. Not for human use. We do not sell to patients.

Fluorofenidone Chemische Struktur

Cas No.: 848353-85-5

Größe Preis Lagerbestand Menge
1mg
61,00 $
Auf Lager
5mg
173,00 $
Auf Lager
10mg
296,00 $
Auf Lager
25mg
591,00 $
Auf Lager
50mg
999,00 $
Auf Lager
100mg
1.785,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway[1][2].

[1]. Qin J, et al. Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology (Carlton). 2013 Oct;18(10):690-9. [2]. Lou Q, et al. Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones. Molecules. 2012 Jan 17;17(1):884-96.

Bewertungen

Review for Fluorofenidone

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fluorofenidone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.